Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 21Active not recruiting 13Unknown 6Withdrawn 5Not yet recruiting 3Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Genitourinary 1

Conditions

Rectal Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × dostarlimab × Clear all
NCT04779151 2025-12-01

NIRADO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated
51 enrolled
GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

University of Iowa

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡